key: cord-1028142-f5tz14de authors: Rodgers, Aoife; Nadkarni, Manasi; Indreberg, Emilie Kruke; Alfallaj, Lenah; Kabir, Zubair title: Smoking and COVID-19: A Literature Review of Cohort Studies in Non-Chinese Population Settings date: 2021-01-22 journal: Tob Use Insights DOI: 10.1177/1179173x20988671 sha: d33cf66df01c81c8cd8989c319ce11987043abb3 doc_id: 1028142 cord_uid: f5tz14de BACKGROUND: Smoking history and its potential association with COVID-19 has attracted many researchers and the lay public alike. However, the studies published to date have several methodological limitations and are mainly from China. We set out to synthesize evidence on smoking and COVID-19 relationship drawn on cohort studies only which are published in non-Chinese population settings. METHOD: A systematic literature search was undertaken drawn on predefined eligibility criteria and a comprehensive search strategy following the PRISMA guideline between January 2020 and August 2020, excluding preprints and gray literature. Three specific outcomes were examined: smoking history, SARS-CoV2 infection, and COVID-19 severity. RESULTS: Of an eligible 40 full-text studies, 7 cohort studies outside of China were finally included in this literature review through independent reviewing. Four studies were from the UK, 2 from the United States, and 1 from Turkey. The sample size ranged from 200 to more than 5000 participants. The findings broadly point to 1 direction, a higher smoking prevalence and an increased risk of smoking history on both SARS-CoV2 infection and on COVID-19 severity. CONCLUSION: A smoking history (either current or past) seems to negatively impact both SARS-CoV2 infection and COVID-19 severity. However, such an observation strengthens the argument to continue smoking cessation efforts both for individuals and for the general population health and well-being. COVID-19 is now well-established as a global pandemic, contributing to thousands of deaths while SARS-CoV2 has infected millions of people across the globe. 1 As the disease evolves, it is important to explore the underlying determinants and the epidemiologic pattern of COVID- 19 . There has been an explosion of COVID-19-related publications, both as preprints and in peer-reviewed journals. 2 Therefore, it is important that evidence is synthesized on specific aspects of the epidemiology of COVID-19 for informing existing targeted public health strategies, which may have been impacted by the current pandemic. One such determinant is smoking, which causes approximately 8 million deaths each year across the globe before the pandemic. 3 Therefore, any potential association between smoking and COVID-19 would be a public health opportunity for tackling both the current pandemic and the tobacco epidemic toward population health and wellbeing. Evidence to date on the potential association between smoking and COVID-19 is patchy and mixed. [4] [5] [6] In the early days of the pandemic, the evidence available to the global audience was mostly from China. The first systematic review on smoking and COVID-19 that was published in March 2020 included 5 studies -all from China. 7 Since then, several systematic reviews were published which included studies mainly from China but were mostly preprints. 5, 6 A rapid "living" systematic review is also available -initially as a pre-print. 8 The Lancet has acknowledged the importance of preprints but reiterated quality. 9 A recent review of systematic reviews on smoking and COVID-19 has highlighted several methodological limitations of the systematic reviews published to date, such as small sample size, selection bias, and the lack of generalisability. 10 Therefore, we set out to address few of these potential gaps through a comprehensive literature review of smoking and COVID-19 including only cohort studies from settings outside of China which are peerreviewed journal publications in English. The overarching research question was "Are individuals with a smoking history at an increased risk of developing SARS-CoV2 infection, COVID-19 disease severity or mortality compared to those without a smoking history"? Search strategy and selection criteria 2 Tobacco Use Insights the evidence synthesis. The studies identified by this search were further analyzed for their eligibility. Study characteristics of the selected studies (n = 8) are shown in Table 1 . The PRISMA flowchart is available as Figure 1 . The final number of cohort studies (both prospective and retrospective) included for narrative synthesis were 7 (all outside of China). Depending on the outcome of each study, the data presented in Table 2 reflects the heterogeneity of each study. The 3 outcomes presented for the exposure of interest (a smoking history -either a former smoker or a current smoker, as defined in each study) were: (1) smoking prevalence by subgroups; (2) severity of SARS-CoV2 infection (as demonstrated in each study of being hospitalized); (3) mortality (COVID-19-related deaths). If information on gender is available in any of the studies related to the above 3 outcomes, Table 2 also captures this. No quality appraisal was undertaken because of the nature of this literature review. A comprehensive search of PubMed between January 1, 2020 and August 30, 2020 yielded 40 peer-reviewed publications in non-Chinese population settings in alignment with our eligibility criteria of including only cohort studies. Of these 40 eligible, only 7 were finally included following full-text reviewing by 2 independent reviewers (AF & MN), and any conflicts were resolved by a third reviewer (ZK). Two of these 7 studies were from the United States, 11,15 1 from Turkey 14 and the remaining 4 were from the United Kingdom. [12] [13] [14] [15] [16] 17 The sample populations in all these 7 studies were individuals who tested positive for COVID-19 from a target population. The population sample ranged from 200 (Bronx, US) to 502,640 (UK) patients. All the studies included were cohort studies ( Table 2 ). The findings of this review are summarized below. We also report adjusted odds ratios where available. Jehi et al 11 in the US of 4536 patients reported significant higher smoking rates (P < .001) among those hospitalized (n = 958) across 2 cohorts (development and validation) -8.6% were current smokers and 36.4% were former smokers compared to 6.9% and 26.3%, respectively, among those who were not hospitalized. Lassele et al 12 in England studying 428,494 individuals using the UK Biobank study reported a similar trend as Jehi et al study: significantly higher smoking rates among those hospitalized (n = 900) compared to those not hospitalized (n = 427,594), 41.9% former smokers and 11.4% current smokers as against 34.6% former and 10% current smokers, respectively. The same study reported significantly higher odds of hospitalizations among former and current smokers compared to non-smokers (1.30; 95% CI:1.10-1.55 and 1.25; 95% CI: 0.96-1.62), respectively, following multivariable regression. Another UK Biobank Study (McQueenie et al 13 ) reported smoking prevalence among those who tested COVID-19 positive (n = 1324) and those who tested negative or were not tested (n = 426,875), 51% were ever smokers (current and former combined) as against 44.6% among those who were negative, respectively. The same study also reported that ever-smokers had an increased risk of testing COVID-19 positive in individuals with no multimorbidity (1.26; 95% CI: 1.02-1.57) in the multivariable analysis. A retrospective cohort study in Istanbul, 14 Turkey of 611 in-patents (Şenkal et al) reported a higher smoking rate (13%) among those defined as severe as compared to those who were categorized as "non-severe" (11%), and this was not significant (P = 0.56). The smallest study (Palaiodimos et al 15 ) in this review (n = 200) of all COVID-19 in-patients from Bronx, New York reported an ever-smoking rate of 32.5%, which is certainly higher than the smoking rate in general population of New York City. The same study reported in the univariate analyses that ever-smokers had higher odds of in-patient mortality (1.19; 95% CI: 0.60-2.36) but in multivariable analyses ever-smoking was found to be protective of inpatient mortality (0.83; 95% CI: 0.37-1.87) albeit not a significant association. However, this study showed that COVID-19 in-patients who were ever-smoking had an increased odds of oxygen requirements in a multivariable analysis (2.10; 95% CI:1.07-4.10). Another UK Biobank study 16 of 7099 participants (Raisi-Estabragh et al) reported that 1439 tested COVID-19 positive. Of these, 50.9% were ever-smokers compared to 51.8% eversmokers among those who tested negative. The same study reported a higher odds (1.26; 95% CI: 1.13, 1.40) of testing COVID-19 positive among ever-smokers when compared to those who were COVID-19 test negative and were not tested (n = 494,838) in the multivariable analyses, but did not reach statistical significance when the untested populations were excluded from the model (1.02; 95% CI: 0.90, 1.15). The largest study 17 in this review included 502,640 participants from the UK Biobank (Woolford et al). 4510 of the participants were tested for COVID-19 and 1326 tested positive. 40% of those who tested positive were former smokers as opposed to 37.8% among those who tested negative. However, 11% were currently smoking among those who tested positive as against 14% among those who tested negative. All these findings were significant when compared with the background population (P < .001). In summary, all the 7 studies included show an apparent higher risk of COVID-19 among the ever-smoking population, and more pronounced among former smokers. This review of cohort studies outside of China examining the relationship of smoking and COVID-19 is an explorative narrative synthesis following a systematic approach, with predefined eligibility criteria and search strategy. The conclusion across all these 7 studies are broadly in the same direction, pointing toward a potential harmful effect of smoking on COVID-19 severity and being more susceptible to contracting SARS-CoV-2 infection. However, the observation of an increased risk of COVID-19 among former smokers is intriguing. This observation is consistent across several studies both included in this review and few of those which did not qualify for this review. 18, 19 This observation needs careful attention and deeper exploration, especially related to timing of quitting smoking, because it is probable that those smokers with morbid conditions could have quit smoking once they were diagnosed with COVID-19. Some of the strengths of this review include the robustness of eligibility criteria of not including pre-prints and to include only cohort studies. Pre-defined eligibility criteria and a comprehensive search strategy also lends support to the rigor of this review. A systematic approach to include studies outside of Chinese population settings may add to the strength of this review for several reasons. First, a systematic review of initial 5 Chinese studies have already been published in March 2020. 7 Second, several systematic reviews post this first systematic review have also been published, majority of these reviews did include studies from China and were preprints. 5, 6 Third, the evolution and the epidemiology of COVID-19 adds to the complexity of reproducibility -and this was evident from the studies published in the initial stage of the pandemic which were mainly from Chinese hospitals and had small population sample. 7 Therefore, these initial studies from China and elsewhere were either cross-sectional or hospital-based and were methodologically weak: selection bias, the lack of generalizability, confounding, and relatively of small sample size. We aimed to address these limitations in our current review by including only cohort studies. Our review has some methodological limitations. We did not undertake a systematic review or a meta-analysis because of the heterogeneity of the papers. Our limit to only published peer-reviewed literature instead of including gray literature may have influenced our search strategy. We searched only 1 database, the PubMed, which is otherwise considered one of the most comprehensive peer-reviewed medical literature databases to date. Finally, not all studies included in this review had all the parameters that we were interested in examining. Examples include, self-reported smoking history (some had no specific distinction between current and former smokers), the lack of adjusted estimates for the specific outcomes of interest, no gender breakdowns, no unified operational definition of "severity" of COVID-19 across the studies reviewed, and the inability to capture "infectiousness" of SARS-CoV2 owing to the nature of the currently COVID-19 diagnostic tests widely employed across these countries. All these methodologically inherent limitations need to be addressed in future research to infer a more concrete conclusion on smoking and COVID-19 progression. Furthermore, the epidemiology and the natural history of this pandemic is evolving. Therefore, it would be premature to speculate on the probable causal mechanism of this observation between a smoking history and SARS-CoV2 infection and its sequelae. Several potential mechanisms have been postulated, especially in relation to upregulation of ACE2 receptors and smoking, and also the role of nicotine on anti-cholinergic pathway. 20, 21 However, the totality of evidence in terms of the global tobacco epidemic remains unaltered, smoking kills 8 million individuals every year globally, and any additional attribution of smoking to SARS-CoV2 infection quite naturally will increase the burden on the current pandemic. Therefore, smoking cessation and avoidance of secondhand smoke exposure must remain the cornerstone of population health and well-being, despite the lingering uncertainty. No personal data were used, therefore no ethical approval was sought World COVID-19 Stats. ncov2019.live. 2020, Updated 2020 The World Health Orgnization Smoking is associated with worse outcomes of COVID-19 particularly among younger adults: a systematic review and metaanalysis The effect of smoking on COVID-19 severity: a systematic review and meta-analysis Current smoking, former smoking, and adverse outcome among hospitalized COVID-19 patients: a systematic review and meta-analysis COVID-19 and smoking: a systematic review of the evidence The association of smoking status with SARS-CoV-2 infection, hospitalisation and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7). Addiction. Published online Preprints with The Lancet are here to stay SARS-CoV-2 and COVID-19: a review of reviews considering implications for public health policy and practice Development and validation of a model for individualized prediction of hospitalization risk in 4,536 patients with COVID-19 Ethnic disparities in hospitalisation for COVID-19 in England: the role of socioeconomic factors, mental health, and inflammatory and pro-inflammatory factors in a community-based cohort study Multimorbidity, polypharmacy, and COVID-19 infection within the UK Biobank cohort Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19 Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher inhospital mortality Renin-angiotensinaldosterone system blockers are not associated with coronavirus disease 2019 (COVID-19) hospitalization: study of 1,439 UK biobank cases COVID-19 and associations with frailty and multimorbidity: a prospective analysis of UK Biobank participants Clinical characteristics of moderate COVID-19 patients aggravation in Wuhan Stadium Cabin Hospital: a 571 cases of retrospective cohort study COVID-19 and Cancer Consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study Smoking upregulates angiotensin-converting enzyme-2 receptor: a potential adhesion site for novel coronavirus SARS-CoV-2 (Covid-19) A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications